{"id":"https://openalex.org/W7224248447","doi":"https://doi.org/10.1080/1120009x.2026.2751380","title":"Time-dependent indirect comparison of enfortumab vedotin plus pembrolizumab and disitamab vedotin plus toripalimab in advanced urothelial carcinoma","display_name":"Time-dependent indirect comparison of enfortumab vedotin plus pembrolizumab and disitamab vedotin plus toripalimab in advanced urothelial carcinoma","publication_year":2026,"publication_date":"2026-10-29","ids":{"openalex":"https://openalex.org/W7224248447","doi":"https://doi.org/10.1080/1120009x.2026.2751380","pmid":"https://pubmed.ncbi.nlm.nih.gov/42954881"},"language":"en","primary_location":{"id":"doi:10.1080/1120009x.2026.2751380","doi":"https://doi.org/10.1080/1120009x.2026.2751380","is_oa":false,"landing_page_url":"https://doi.org/10.1080/1120009x.2026.2751380","pdf_url":null,"source":{"id":"https://openalex.org/S127202688","display_name":"Journal of Chemotherapy","issn_l":"1120-009X","issn":["1120-009X","1973-9478"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029742754","display_name":"Hiroki Tanaka","orcid":"https://orcid.org/0009-0006-3003-3833","observed_orcids":["https://orcid.org/0009-0006-3003-3833"]},"institutions":[{"id":"https://openalex.org/I4400009020","display_name":"Institute of Science Tokyo","ror":"https://ror.org/05dqf9946","country_code":"JP","type":"education","lineage":["https://openalex.org/I4400009020"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroki Tanaka","raw_affiliation_strings":["Department of Urology, Institute of Science Tokyo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Institute of Science Tokyo","institution_ids":["https://openalex.org/I4400009020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032348337","display_name":"Hiroshi Fukushima","orcid":"https://orcid.org/0000-0001-7548-1580","observed_orcids":["https://orcid.org/0000-0001-7548-1580"]},"institutions":[{"id":"https://openalex.org/I4400009020","display_name":"Institute of Science Tokyo","ror":"https://ror.org/05dqf9946","country_code":"JP","type":"education","lineage":["https://openalex.org/I4400009020"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Hiroshi Fukushima","raw_affiliation_strings":["Department of Urology, Institute of Science Tokyo"],"raw_orcid":"https://orcid.org/0000-0001-7548-1580","affiliations":[{"raw_affiliation_string":"Department of Urology, Institute of Science Tokyo","institution_ids":["https://openalex.org/I4400009020"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160131387","display_name":"Wei Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4400009020","display_name":"Institute of Science Tokyo","ror":"https://ror.org/05dqf9946","country_code":"JP","type":"education","lineage":["https://openalex.org/I4400009020"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Wei Chen","raw_affiliation_strings":["Department of Urology, Institute of Science Tokyo","Department of Urology, Zigong Fourth People\u2019s Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Institute of Science Tokyo","institution_ids":["https://openalex.org/I4400009020"]},{"raw_affiliation_string":"Department of Urology, Zigong Fourth People\u2019s Hospital","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160116820","display_name":"Fei Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210103346","display_name":"Nanfang Hospital","ror":"https://ror.org/01eq10738","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210103346"]},{"id":"https://openalex.org/I58200834","display_name":"Southern Medical University","ror":"https://ror.org/01vjw4z39","country_code":"CN","type":"education","lineage":["https://openalex.org/I58200834"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Fei Li","raw_affiliation_strings":["Department of Urology, Nanfang Hospital, Southern Medical University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Nanfang Hospital, Southern Medical University","institution_ids":["https://openalex.org/I4210103346","https://openalex.org/I58200834"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160145176","display_name":"Soichiro Yoshida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4400009020","display_name":"Institute of Science Tokyo","ror":"https://ror.org/05dqf9946","country_code":"JP","type":"education","lineage":["https://openalex.org/I4400009020"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Soichiro Yoshida","raw_affiliation_strings":["Department of Urology, Institute of Science Tokyo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Institute of Science Tokyo","institution_ids":["https://openalex.org/I4400009020"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5089503656","display_name":"Yasuhisa Fujii","orcid":"https://orcid.org/0000-0002-6761-3229","observed_orcids":["https://orcid.org/0000-0002-6761-3229"]},"institutions":[{"id":"https://openalex.org/I4400009020","display_name":"Institute of Science Tokyo","ror":"https://ror.org/05dqf9946","country_code":"JP","type":"education","lineage":["https://openalex.org/I4400009020"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yasuhisa Fujii","raw_affiliation_strings":["Department of Urology, Institute of Science Tokyo"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Urology, Institute of Science Tokyo","institution_ids":["https://openalex.org/I4400009020"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5032348337"],"corresponding_institution_ids":["https://openalex.org/I4400009020"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.89691268,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"1","last_page":"5"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9926999807357788,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/enfortumab-vedotin","display_name":"enfortumab vedotin","score":0.9679999947547913},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9610000252723694},{"id":"https://openalex.org/keywords/disitamab-vedotin","display_name":"disitamab vedotin","score":1.0},{"id":"https://openalex.org/keywords/toripalimab","display_name":"toripalimab","score":1.0},{"id":"https://openalex.org/keywords/advanced-urothelial-carcinoma","display_name":"advanced urothelial carcinoma","score":0.9710000157356262},{"id":"https://openalex.org/keywords/individual-patient-data","display_name":"individual patient data","score":0.6850000023841858},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8029999732971191},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":1.0},{"id":"https://openalex.org/keywords/transitivity","display_name":"transitivity","score":0.6140000224113464}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8270000219345093},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7332000136375427},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6866000294685364},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6599000096321106},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5175999999046326},{"id":"https://openalex.org/C3019882237","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial carcinoma","level":4,"score":0.5},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.429500013589859},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3612000048160553},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.34929999709129333},{"id":"https://openalex.org/C2779699572","wikidata":"https://www.wikidata.org/wiki/Q421052","display_name":"Everolimus","level":2,"score":0.3301999866962433},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.3215999901294708},{"id":"https://openalex.org/C3020745361","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial cancer","level":4,"score":0.3206000030040741},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.3138999938964844},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.3084999918937683},{"id":"https://openalex.org/C50382708","wikidata":"https://www.wikidata.org/wiki/Q223218","display_name":"Proportional hazards model","level":2,"score":0.29989999532699585},{"id":"https://openalex.org/C38180746","wikidata":"https://www.wikidata.org/wiki/Q1952580","display_name":"Multivariate analysis","level":2,"score":0.2822999954223633},{"id":"https://openalex.org/C10515644","wikidata":"https://www.wikidata.org/wiki/Q543310","display_name":"Survival analysis","level":2,"score":0.2806999981403351},{"id":"https://openalex.org/C3018260909","wikidata":"https://www.wikidata.org/wiki/Q1322871","display_name":"Exploratory analysis","level":2,"score":0.26260000467300415},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2563999891281128},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.2500999867916107}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1080/1120009x.2026.2751380","doi":"https://doi.org/10.1080/1120009x.2026.2751380","is_oa":false,"landing_page_url":"https://doi.org/10.1080/1120009x.2026.2751380","pdf_url":null,"source":{"id":"https://openalex.org/S127202688","display_name":"Journal of Chemotherapy","issn_l":"1120-009X","issn":["1120-009X","1973-9478"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Chemotherapy","raw_type":"journal-article"},{"id":"pmid:42954881","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42954881","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of chemotherapy (Florence, Italy)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1982967337","https://openalex.org/W2005947177","https://openalex.org/W2118167354","https://openalex.org/W2140699272","https://openalex.org/W2768492030","https://openalex.org/W3163923489","https://openalex.org/W3205114076","https://openalex.org/W3212805030","https://openalex.org/W4311928016","https://openalex.org/W4392498919","https://openalex.org/W4394746364","https://openalex.org/W4399868663","https://openalex.org/W4415340539","https://openalex.org/W7128163342","https://openalex.org/W7165202675"],"related_works":["https://openalex.org/W4410929528","https://openalex.org/W4386530351","https://openalex.org/W7214060134","https://openalex.org/W7162877118","https://openalex.org/W7214059338","https://openalex.org/W4405135077","https://openalex.org/W7125177873","https://openalex.org/W4407699870","https://openalex.org/W7214060338","https://openalex.org/W7214059634"],"abstract_inverted_index":{"Enfortumab":[0],"vedotin":[1,7],"plus":[2,8],"pembrolizumab":[3],"(EV-P)":[4],"and":[5,23,49,55,82,88,101],"disitamab":[6],"toripalimab":[9],"(DV-T)":[10],"improved":[11],"first-line":[12],"outcomes":[13],"in":[14],"the":[15,24,62],"global":[16],"phase":[17,26],"III":[18,27],"EV-302/KEYNOTE-A39":[19],"trial":[20,29],"(all-comer":[21],"population)":[22],"Chinese":[25],"RC48-C016":[28],"(HER2-expressing":[30],"tumours),":[31],"respectively,":[32],"but":[33],"no":[34,119],"head-to-head":[35],"comparison":[36],"is":[37],"available.":[38],"We":[39],"reconstructed":[40],"individual":[41],"patient":[42],"data":[43],"from":[44],"published":[45],"overall":[46],"survival":[47,51],"(OS)":[48],"progression-free":[50],"(PFS)":[52],"Kaplan-Meier":[53],"curves":[54],"performed":[56],"time-dependent":[57],"anchored":[58],"indirect":[59],"comparisons":[60],"through":[61,104],"randomised":[63],"platinum-gemcitabine":[64],"control":[65],"arms.":[66],"Anchored":[67],"PFS":[68,112],"ratios":[69,73],"of":[70],"treatment":[71],"hazard":[72],"(RHRs)":[74],"were":[75,94],"1.41":[76],"(95%":[77],"CI":[78],"0.86-2.30),":[79],"1.02":[80],"(0.63-1.66)":[81],"0.62":[83],"(0.20-1.89)":[84],"at":[85],"0-6,":[86],"6-12":[87],"12-18":[89],"months.":[90,106],"Corresponding":[91],"OS":[92,117],"RHRs":[93,113],"0.78":[95],"(0.36-1.66),":[96],"1.07":[97],"(0.61-1.88),":[98],"0.74":[99],"(0.34-1.62)":[100],"0.48":[102],"(0.16-1.47)":[103],"24":[105],"Continuous":[107],"spline":[108],"analyses":[109],"suggested":[110],"declining":[111],"over":[114],"time,":[115],"whereas":[116],"showed":[118],"consistent":[120],"pattern;":[121],"all":[122],"95%":[123],"CIs":[124],"included":[125],"1.":[126],"Population":[127],"heterogeneity":[128],"limits":[129],"transitivity.":[130],"These":[131],"exploratory":[132],"findings":[133],"do":[134],"not":[135],"establish":[136],"superiority,":[137],"equivalence":[138],"or":[139],"interchangeability.":[140]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2026-10-30T00:00:00"}